Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
Application Due Date(s): May 21, 2020; November 19, 2020; May 20, 2021; November 18, 2021
PAR-20-116 Expiration Date November 19, 2021
Application budgets are limited to $475,000 in direct costs per year and need to reflect the actual needs of the proposed project
The maximum project period is 4 years.